{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2019-07-23T17%3A00%3A03.223Z&min-ddpCreated=2019-07-23T17%3A00%3A00.257Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1141380", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1141380/answer", "answerText" : {"_value" : "
As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA\u2019s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.<\/p>
The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-25T16:35:38.84Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "MMR Vaccine: Safety"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1522", "label" : {"_value" : "Biography information for Adam Holloway"} } , "tablingMemberConstituency" : {"_value" : "Gravesham"} , "tablingMemberPrinted" : [{"_value" : "Adam Holloway"} ], "uin" : "280998"} , {"_about" : "http://data.parliament.uk/resources/1141381", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1141381/answer", "answerText" : {"_value" : "
Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service\u2019s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer\u2019s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.<\/p>
A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:<\/p>